KIT codon 558 insertions in gastrointestinal stromal tumors. Analysis of 17 rare KIT mutants

Human Pathology

Volumn 39, Issue 12, 2008, Pages 1728-1736

  Lasota, Jerzy ^a   Kuban, Wojciech ^b   Wardelmann, Eva ^c   Debiec Rychter, Maria ^d   Merkelbach Bruse, Sabine ^c   Sciot, Raf ^d   Rys, Janusz ^e   Steigen, Sonja E ^f   Iwanik, Katarzyna ^g   Holden, Joseph A ^h   Jerzak vel Dobosz, Anna ⁱ   Schildhaus, Hans Ulrich ^c   Miettinen, Markku ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f UNIVERSITY OF TROMSØ   (Norway)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Exon 11; GIST; Insertion; KIT; Mutation

Indexed keywords

ASPARAGINE; DNA POLYMERASE; GLUTAMINE; LYSINE; PROLINE;

ADULT; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CODON; DNA FLANKING REGION; DNA REPAIR; DNA REPLICATION; DNA STRAND; ENZYME ACTIVITY; EPITHELIOID CELL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE INSERTION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; KIT GENE; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CODON; DNA, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTESTINAL NEOPLASMS; MALE; MESENCHYMOMA; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PROTO-ONCOGENE PROTEINS C-KIT; RECTAL NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 55949083057     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.05.011     Document Type: Article

References (42)

1. Miettinen M., and Lasota J. Pathology and prognosis of gastrointestinal stromal tumors at different sites. Semin Diagn Pathol 23 (2006) 70-83
2. Kitamura Y., and Hirota S. Kit as human oncogenic tyrosine kinase. Cell Mol Life Sci 61 (2004) 2924-2931
3. Huizinga J.D. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 47 (1999) 239-247
4. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 (1998) 1259-1269
5. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38 (2002) S3-S10
6. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
7. Lasota J., and Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23 (2006) 91-102
8. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
9. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59 (1999) 4297-4300
10. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 (2001) 8118-8121
11. Andersson J., Sjogren H., Meis-Kindblom J.M., et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160 (2002) 15-22
12. Wardelmann E., Neidt I., Bierhoff E., et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15 (2002) 125-136
13. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
14. Subramanian S., West R., Corless C.L., et al. Gastrointestinal stromal tumors (GISTs) wit KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23 (2004) 7780-7790
15. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
16. Rossi G., Sartori G., Valli R., et al. The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J Clin Pathol 58 (2005) 991-993
17. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
18. Steigen S.E., Eide T.J., Wasag B., et al. Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. APMIS 115 (2007) 289-298
19. Kontogianni-Katsarou K., Dimitriadis E., Lariou C., et al. KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World J Gastroenterol 14 (2008) 1891-1897
20. Lasota J., Dansonka-Mieszkowska A., Stachura T., et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16 (2003) 1257-1264
21. Lasota J., Kopczynski J., Sarlomo-Rikala M., et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34 (2003) 1306-1312
22. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., et al. A great majority of GISTs with PDGFRA mutations represents gastric tumors of low or no malignant potential. Lab Invest 84 (2004) 874-883
23. Wardelmann E., Hrychyk A., Markelbach-Bruse S., et al. Association of platelet-derived growth factor receptor α mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6 (2004) 197-204
24. Wasag B., Debiec-Rychter M., Pauwels P., et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 17 (2004) 889-894
25. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors (GISTs) of the stomach-a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
26. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
27. Sarlomo-Rikala M., Tsujimura T., Lendahl U., et al. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 110 (2002) 499-507
28. Markham N.R., and Zuker M. DINAMelt web server for nucleic acid melting prediction. Nucleic Acids Res 33 (2005) W577-W581
29. Lasota J., and Miettinen M. KIT exon 11 deletion-inversions represent complex mutations in gastrointestinal stromal tumors. Cancer Genet Cytogenet 175 (2007) 69-72
30. Tuveson D.A., Willis N.A., Jacks T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20 (2001) 5054-5058
31. Maki H. Origins of spontaneous mutations: specificity and directionality of base-substitution, frameshift, and sequence-substitution mutageneses. Annu Rev Genet 36 (2002) 279-303
32. Akgün E., Zahn J., Baumes S., et al. Palindrome resolution and recombination in the mammalian germ line. Mol Cell Biol 17 (1997) 5559-5570
33. Roth D.B., and Wilson J.H. Illegitimate recombination in mammalian cells. In: Kucherlapati R., and Smith G.R. (Eds). In Genetic recombination (1988), American Society for Microbiology, Washington, DC 621-653
34. Andersson J., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130 (2006) 1573-1581
35. Agaimy A., Wunsch P.H., Hofstaedter F., et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31 (2007) 113-120
36. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106 (2003) 887-895
37. Martin J., Poveda J., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 (2005) 6190-6198
38. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
39. Demetri G.D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 38 Suppl 5 (2002) S52-S59
40. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
41. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 42 (2006) 1093-1103
42. Nakagomi N., and Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systematic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 87 (2007) 365-371